Founded with a mission to revolutionize regenerative medicine, Cellino is dedicated to developing an AI-guided single-cell laser editing platform for cell-based therapies. The company focuses on automating and standardizing autologous stem cell production, aiming to accelerate the development of life-saving medical treatments. By leveraging cutting-edge technology, Cellino seeks to make personalized regenerative therapies more accessible and scalable, targeting a broad market within the healthcare industry.
Cellino has attracted notable investors and industry leaders, contributing to its rapid growth and innovation. The company's achievements include the successful development of a scalable platform that enhances the efficiency and precision of stem cell production. This breakthrough has significant implications for the future of personalized medicine, positioning Cellino as a key player in the field of regenerative therapies.
